Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma—RReview
Chimeric antigen receptor T(CAR-T)cell therapy is a rapidly developing new immunotherapy in recent years.Compared with other therapies,CAR-T has significant advantages for high-risk and relapsed/refractory B cell non-Hodgkin's lymphoma(B-NHL)patients.Currently,a variety of anti-CD19 CAR-T cells have been approved by the FDA for the treatment of B-NHL,such as axicabtagene ciloleucel,tisagenlecucel,lisocababtagene maraleucel and brexucabtagene autoleucel.In addition,many studies are actively exploring and developing different targeted CAR-T cells,which show great potential in B-NHL.This review briefly summarized the latest research progress on the application of CAR-T in common B-NHL.
NETL
NSTL
万方数据
维普
